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Abstract
In this paper, we develop new methods for estimating average treatment effects
in observational studies, in settings with more than two treatment levels, assuming
unconfoundedness given pre-treatment variables. We emphasize propensity score sub-
classification and matching methods which have been among the most popular methods
in the binary treatment literature. Whereas the literature has suggested that these par-
ticular propensity-based methods do not naturally extend to the multi-level treatment
case, we show, using the concept of weak unconfoundedness and the notion of the
generalized propensity score, that adjusting for a scalar function of the pre-treatment
variables removes all biases associated with observed pre-treatment variables. We apply
the proposed methods to an analysis of the effect of treatments for fibromyalgia. We
also carry out a simulation study to assess the finite sample performance of the methods
relative to previously proposed methods.
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1 Introduction
There is an extensive theoretical and empirical literature on estimating average causal effects
of binary treatments in observational studies based on the assumption of unconfoundedness
or ignorable treatment assignment. Under this assumption differences in outcomes for units
with different treatment levels, but the same values for pre-treatment variables, can be
interpreted as estimates of causal effects. Much of the literature builds on the seminal paper
by Rosenbaum & Rubin (1983) (RR83 from here on) which clarified the central role of
the propensity score (the conditional probability of receiving the treatment given the pre-
treatment variables or covariates) in analyses of causal effects in such settings, and which
proposed a number of widely used estimators. See Imbens & Rubin (2015) for a textbook
treatment.
Although important for empirical practice, much less theoretical work has been done on
the setting with more than two treatment levels (exceptions include Imbens, 2000; Robins, et
al., 2000; Lechner, 2001; Foster, 2003; Hirano & Imbens, 2004; Imai & Van Dyk, 2004; Cole
& Frangakis, 2009; Cadarette et al., 2010; Cattaneo, 2010; McCaffrey et al., 2013; Rassen
et al., 2013). Because in settings with multi-level treatments there is no scalar function of
the covariates that has all the properties that RR83 presents for the propensity score in the
binary treatment case, it has been claimed that there is no natural analogue to matching
and subclassification on the propensity score (Imbens, 2000; Lechner, 2001; Rassen et al.,
2013).
In the main contribution of the current paper we show that, contrary to these claims,
the essence of the results in RR83 generalizes to the setting with multi-level treatments.
In particular, we develop methods for matching and subclassification on scalar functions of
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the covariates that are valid irrespective of the number of distinct levels for the treatment.
The key insight is that we do not construct sets of units with the balancing property that
within these sets the treatment level is independent of the covariates. Doing so would require
adjusting for the vector of propensity scores with length equal to the number of treatment
levels minus one. Instead we focus on estimating the average of the potential outcomes
separately for each treatment level, which requires adjusting only for the probability of
receiving that particular level of the treatment. This insight allows us to extend some of
the most widely used methods for the binary treatment case to the multi-level treatment
case without giving up the dimension reducing property of the propensity score. We provide
some simulation evidence that demonstrates the relevance of concerns with the previously
proposed estimators and the promise of the new methods.
2 Set Up
Following Rubin (1974) and RR83 we use the potential outcome set up, generalized to the
case with more than two, unordered, levels for the treatment in Imbens (2000), Lechner
(2001), Imai & Van Dyk (2004), and Cattaneo (2010). The treatment is denoted by Wi ∈
W = {1, . . . , T}. In the standard binary treatment case T = 2, the two treatments are often
labeled treatment and control. For each unit i there are T potential outcomes, one for each
treatment level, denoted by Yi(w), for w ∈W. Implicitly in this notation is the assumption
that there is no interference between units and no versions of each treatment level (the
stable-unit-treatment-value assumption, or sutva, Rubin, 1978). The observed outcome for
unit i is the potential outcome corresponding to the treatment received:
Y obsi = Yi(Wi).
We also observe a vector-valued covariate or pre-treatment variable, denoted by Xi. These
pre-treatment variables are known a priori not to be affected by the treatment, typically
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measured prior to the determination of the treatment level, and so there are no multiple
versions of these covariates corresponding to the different levels of the treatment. These
pretreatment variables may include fixed attributes of the units, or measurements prior to the
treatment assignment that predict the outcome, for example prior health status. Although
we do not stress this in the notation, there is implicitly a temporal aspect to the study with
three stages: first, the pre-treatment variables are measured, or at least they assume their
values prior to the assignment of the treatment; second, the treatment is assigned or selected;
third, the outcome assumes its value and is measured.
We assume the sequence (W1, X1, Y1(1), . . . , Y1(T )), . . . , (WN , XN , YN(1), . . . , YN(T )) with
the potential outcomes is i.i.d., so that the sequence of realized values (W1, X1, Y obs1 ), . . . , (WN ,
XN , Y
obs
N ) is also i.i.d.
Following the literature (e.g., RR83), we focus on average treatment effects as the causal
estimands. This is less restrictive than it may appear at first because we can first take
transformations of the outcomes and pre-treatment variables. For the comparison between
treatment levels w and w′, the average effect is
τ(w,w′) = E[Yi(w′)− Yi(w)]. (1)
The expectation is taken with respect to the same population (called the target population,
Frolich, 2004a) for different treatment-level pairs (w,w′). Some researchers, when analyzing
data with multi-level treatments, have used conventional methods for comparing two treat-
ment levels at a time. Often such analyses use only information on units exposed to one of
those two treatment levels, which would lead to estimates of E[Yi(w′)−Yi(w) | Wi ∈ {w,w′}].
If the subpopulation of units with treatment levels w or w′ is different in terms of poten-
tial outcome distributions, these estimands are generally different from the τ(w,w′) defined
in (1), because the latter do not condition on Wi ∈ {w,w′}. As a result such binary-
comparison analyses make it difficult to compare E[Yi(w′) − Yi(w) | Wi ∈ {w,w′}] and
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E[Yi(w′′)− Yi(w) | Wi ∈ {w,w′′}] because they refer to different populations.
In this paper we mainly focus on the case where the different treatment levels are qualit-
atively distinct. In that cases the interest is typically in average effects of the form τ(w,w′).
In other cases, however, the treatment levels may measure the quantity of a dose. In such
cases the researcher may be interested in weighted combinations of average effects. For ex-
ample, one might be interested in
∑T−1
w=1 λwτ(w,w + 1), with the weights adding up to one,
which would correspond to a weighted average of unit increases in the dose. One advantage
of such estimands is that their variance may be lower than that for particular τ(w,w′). In
this case there may also be particular interest in τ(1, T ), the effect of the maximum dose.
Our results also apply to all such estimands.
3 Weak and Strong Unconfoundedness and the General-
ized Propensity Score
Our focus is on observational studies where assignment to treatment is not completely ran-
dom. Instead, following a large strand of the observational studies literature, we assume that
assignment to treatment is unconfounded so that, within subpopulations that are homogen-
ous in observed pre-treatment variables, assignment to treatment is as good as random. This
is strictly weaker than complete randomization by allowing for general associations between
the treatment level and the pre-treatment variables.
3.1 The generalized propensity score
In this section we discuss the generalization of the notion of the propensity score, introduced
in the causality literature by RR83 for the binary treatment case, to our setting with multi-
level treatments. In the binary treatment case RR83 defines the propensity score as the
conditional probability of receiving the active treatment rather than the control treatment,
p(x) = pr(Wi = 1 | Xi = x). Here we generalize that to the multi-level treatment case,
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following Imbens (2000):
Definition 1 (Generalized Propensity Score) The generalized propensity score is the condi-
tional probability of receiving each treatment level:
p(w | x) = pr(Wi = w | Xi = x).
3.2 Overlap
Before formally discussing unconfoundedness assumptions, let us assume that there is overlap
in the covariate distributions:
Assumption 1 (Overlap) For all values of x the probability of receiving any level of the
treatment is positive:
p(w | x) > 0 for all w, x.
Without this assumption there will be values of x for which we cannot estimate the average
effect of some treatments relative to others without relying on extrapolation. In Section 6
we discuss methods for constructing a subsample with better overlap for cases where this
assumption is (close to) violated.
3.3 Strong unconfoundedness
We start by generalizing the conventional RR83 version of the unconfoundedness assumption
to the case with multi-level treatments. We refer to this as strong unconfoundedness to
distinguish it from the weaker condition of weak unconfoundedness.
Definition 2 (Strong Unconfoundedness) The assignment mechanism is strongly uncon-
founded if
Wi ⊥⊥
(
Yi(1), . . . , Yi(T )
)
| Xi.
6
Here we use the ⊥⊥ notation introduced by Dawid (1979) to denote (conditional) independ-
ence.
The assumption of strong unconfoundedness has no testable implications. In a particular
application the assumption is a substantive one, and often a controversial one. Often it can
be made more plausible by collecting detailed information at baseline on characteristics of
the units that are related to treatment and outcome. As a result the dimension of Xi may
be high.
One implication of strong unconfoundedness is the following extension of the propensity
score result in RR83 to the multi-level treatment case:
Lemma 1 (RR83) Suppose the assignment mechanism is strongly unconfounded. Then
Wi q
(
Yi(1), . . . , Yi(T )
) ∣∣∣(p(1 | Xi), . . . , p(T − 1 | Xi)) .
Because
∑T
w=1 p(w|x) = 1, it follows that p(T |x) is a linear combination of p(1|x), . . . , p(T −
1|x), and so we do not need to include p(T |x) in the conditioning set. If there are two levels
of the treatment, the result in the lemma reduces to the result in RR83. As pointed out
in Imbens (2000) and Rassen et al. (2013), the dimension reduction property of the lemma
depends on the number of distinct levels for the treatment, and therefore the result is less
useful in settings with a substantial number of treatment levels. The problem is that without
additional assumptions there is in general no scalar function b(x) of the covariates such that
Wi ⊥⊥ (Yi(1), . . . , Yi(T )) | b(Xi), suggesting that the advantages of the propensity score
approach do not carry over to the multi-level treatment case. Joffe & Rosenbaum (1999);
Lu et al. (2001); Imai & Van Dyk (2004); Zanutto, Lu, & Hornik (2005) discuss additional
assumptions under which functions b(·) exist with this property and whose dimension is
lower than T − 1. In particular, Lu et al. (2001) assume that a scalar balancing function b(·)
exists and propose a matching estimator based on b(·), and Zanutto, Lu, & Hornik (2005)
propose a subclassification estimator under this assumption. Nevertheless, in general such
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functional form assumptions may be controversial.
3.4 Weak unconfoundedness
We improve the dimension reduction property of the generalized propensity score by weaken-
ing the requirement of strong unconfoundedness condition to weak unconfoundedness. Define
the T indicator variables Di(w) ∈ {0, 1}:
Di(w) =

1 if Wi = w,
0 otherwise.
In terms of these indicator variables strong unconfoundedness is equivalent to
(
Di(1), . . . , Di(T − 1)
)
⊥⊥
(
Yi(1), . . . , Yi(T )
)
| Xi.
Now we can formulate the weak unconfoundedness notion, introduced in Imbens (2000).
Definition 3 (Weak unconfoundedness) The assignment mechanism is weakly unconfounded
if for all w ∈W,
Di(w) ⊥⊥ Yi(w) | Xi.
Although formally it is obviously weaker, we do not wish to argue that weak unconfoun-
dedness is substantively weaker than strong unconfoundedness. In fact neither have testable
implications, and there appear to be no interesting estimands that are identified under the
stronger assumption but not under the weaker assumption. Rather, the two key insights, and
the motivation for distinguishing between the two unconfoundedness assumptions, are, one,
that, as shown in Lemma 2 below, weak unconfoundedness is preserved if we condition on a
scalar function of the pretreatment variables, whereas preserving strong unconfoundedness
requires conditioning on a set of T − 1 functions of the pre-treatment variables, as shown in
Lemma 1, and two, that weak unconfoundedness is sufficient for identifying average causal
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effects, as formalized in Lemma 3 below.
Lemma 2 (Weak Unconfoundedness) Suppose the assignment mechanism is weakly uncon-
founded. Then for all w ∈W,
Di(w) ⊥⊥ Yi(w) | p(w|Xi).
Lemma 3 (Average Causal Effects Under Weak Unconfoundedness) Suppose the assignment
mechanism is weakly unconfounded. Then
E[Yi(w′)− Yi(w)] = E
[
E[Y obsi | Wi = w′, p(w′ | Xi)]
]
− E
[
E[Y obsi | Wi = w, p(w | Xi)]
]
.
Lemma 3 is the key result. For its interpretation it is useful to compare it to the standard
result under strong unconfoundedness. Under the strong unconfoundedness assumption we
create subpopulations where we can simultaneously compare units with all different levels of
the treatment, leading to
E[Yi(w′)− Yi(w)]
= E
[
E[Y obsi | Wi = w′, p(1 | Xi), . . . , p(T−1|Xi)]
]
−E
[
E[Y obsi | Wi = w, p(1 | Xi), . . . , p(T−1 | Xi)]
]
= E
[
E[Yi(w′)− Yi(w) | p(1 | Xi), . . . , p(T − 1|Xi)]
]
To allow for comparisons of all treatments these subpopulations were defined by common
values for the full set of T − 1 propensity scores (p(1 | Xi), . . . , p(T − 1 | Xi)). Under weak
unconfoundedness we do not, and in fact cannot, construct such subpopulations. However,
in order to estimate the average effect E[Yi(w′)−Yi(w)] it is not necessary to do so. Instead,
we construct, for each treatment level w separately, subpopulations where we can estimate
the average value of the potential outcomes, but only for that single treatment level. For
treatment level w these subpopulations are defined by the value of a single score, p(w|Xi),
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leading to the equality
E[Yi(w)] = E
[
E[Y obsi | Wi = w, p(w | Xi)]
]
.
That difference in focus allows us to reduce the dimension of the conditioning variable to a
scalar, irrespective of the number of treatment levels.
4 Matching
In this section we discuss matching methods. First we discuss conventional matching on
the full set of pre-treatment variables. This is not a new method, but it will be useful to
contrast with the proposed methods. Then we discuss how the generalized propensity score
can be used to develop a new matching estimator that matches only on a scalar function of
the pre-treatment variables.
4.1 Matching
Frölich (2004b) demonstrates covariate matching in multi-level treatments. Here we focus on
nearest neighbor matching. Other modifications include multiple nearest neighbors match-
ing, kernel matching and so forth. Reviews of general matching methods can be found in
Imbens (2004); Imbens & Rubin (2015); Huber, Lechner & Wunsch (2013). Define the cov-
ariate matching functionmcov :W×X 7→ {1, . . . , N} as the index for the unit with treatment
level w that is closest to x in terms of covariates (ignoring ties):
mcov(w, x) = arg min
j:Wj=w
||Xj − x||.
Here we use || · || to denote a generic metric. In practice one would typically use the Mahala-
bonis metric, where ||x−x′|| = {(x−x′)TV −1(x−x′)}1/2, with V =∑i(Xi−X)(Xi−X)T/N ,
and X =
∑
iXi/N . Note that the set of indices we search over includes all units, includ-
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ing unit i itself, so that for all i, mcov(Wi, Xi) = i. Given the covariate matching function
mcov(w, x) the potential outcomes for unit i are imputed as
Yˆi(w) = Y
obs
mcov(w,Xi)
,
for w = 1, . . . , T . Now we estimate τ(w,w′) as
τˆcov(w,w
′) = N−1
N∑
i=1
(
Y obsmcov(w′,Xi) − Y obsmcov(w,Xi)
)
. (2)
Note that to estimate τ(w,w′) we impute potential outcomes Yi(w) and Yi(w′) even for units
who did not receive either treatment level w or w′. This ensures comparability of average
treatment effects for different pairs of treatments.
4.2 Matching on the Generalized Propensity Score
Just as in the binary treatment setting, matching on all covariates is not an attractive
procedure in the multi-level treatment setting if the number of covariates is substantial
(e.g., Abadie & Imbens, 2006; Imbens & Rubin, 2015; Imai & Van Dyk, 2004). In the binary
treatment case RR83 proposed matching on the propensity score to reduce the dimensionality
of the matching problem. If p(1|x) is the Rosenbaum-Rubin propensity score, the matching
function for the binary treatment case would be
mbinaryps (w, p) = arg min
j:Wj=w
||p(1|Xj)− p||. (3)
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One could generalize that to the multi-level treatment case by matching on the full set of
scores, leading to
mmultilvlgps (w, p1, . . . , pT−1) = arg min
j:Wj=w
∥∥∥∥∥∥∥∥∥∥

p(1|Xj)− p1
...
p(T − 1|Xj)− pT−1

∥∥∥∥∥∥∥∥∥∥
. (4)
Here we generalize this to the case with multi-level treatments in a way that allows
for a scalar matching variable. In this case matching is conceptually quite different from
matching on covariates. We separate the estimation of τ(w,w′) = E[Yi(w′)]− E[Yi(w)] into
the two terms. First we focus on the problem of estimating E[Yi(w)]. Define the generalized
propensity score matching function as
mgps(w, p) = arg min
j:Wj=w
||p(w|Xj)− p||. (5)
Here the treatment level w enters into the matching function not only by limiting the set of
potential matches to the set of units with Wj = w, but also in the function of the covariates
that is being matched, p(w|Xj). In covariate and conventional propensity score matching
the treatment level only affects the set of potential matches.
Given the generalized propensity score matching function we impute Yi(w) as
Yˆi(w) = Y
obs
mgps(w,p(w|Xi)).
The average effect is estimated as
τˆgps(w,w
′) = N−1
N∑
i=1
(
Y obsmgps(w′,p(w′|Xi)) − Y obsmgps(w,p(w|Xi))
)
. (6)
Note that the difference Y obsmgps(w′,p(w′|Xi))−Y obsmgps(w,p(w|Xi)) in (6) is not generally an estimate of
an average causal effect, whereas in (2) the difference Y obsmcov(w′,Xi)−Y obsmcov(w,Xi) is an estimate of
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the average causal effect E[Yi(w′)−Yi(w) | Xi]. In the binary treatment case this distinction
between covariate and propensity score matching does not matter: in that case there are
only two values for w, w = 1, 2, so that p(1 | x) = 1 − p(2 | x), and therefore matching on
p(1 | x) is the same as matching on both p(1 | x) and p(2 | x), and the same as matching on
p(2 | x).
In Web Appendix, we provide mathematical details for inference and show that under
mild regularity conditions, the matching estimator based on the generalized propensity score
or the estimated generalized propensity score is asymptotically normally distributed.
5 Subclassification on the Generalized Propensity Score
In the binary treatment literature, a common alternative to matching is subclassification or
stratification on the propensity score, originally proposed by RR83. To put our proposed
methods for the multi-level treatment case in perspective, let us briefly summarize their
approach for the binary treatment case in our current notation to show why it does not
directly extend to the multivalued treatment case. Divide the sample into a number of
subclasses by the value of the propensity score p(1|x). Based on Cochran (1968) who shows
that this removes much of the bias, researchers often use five subclasses. To be specific, let
q
p(1|x)
j be the jth quintile of the empirical distribution of p(1|Xi), for j = 1, . . . , 4, and define
q
p(1|x)
0 = 0 and q
p(1|x)
5 = 1. Then we construct the five subclasses, based on the propensity
score being between qp(1|x)j−1 and q
p(1|x)
j . For subclass j one can estimate the average causal
effect of treatment 1 versus treatment 2 as
τj(1, 2) =
1
Nj2
∑
i:q
p(1|x)
j−1 <p(1|Xi)≤qp(1|x)j ,Wi=2
Y obsi −
1
Nj1
∑
i:q
p(1|x)
j−1 <p(1|Xi)≤qp(1|x)j ,Wi=1
Y obsi ,
13
where Njw is the number of units in subclass j with treatment level w. The overall average
treatment effect is then estimated by averaging over the subclasses:
τˆ(1, 2) =
5∑
j=1
Nj1 +Nj2
N
· τˆj(1, 2).
Because all Nj1 + Nj2 are close to equal, at most differ by 1, (assuming there are no ties)
this is essentially a simple arithmetic mean of the J estimates τˆj(1, 2).
Now consider the multi-level treatment case. We are interested in τ(w,w′) for some pair
of treatment levels w and w′. Again, and this is a cornerstone of our approach, we write this
as a difference of two expectations, τ(w,w′) = E[Yi(w′)]− E[Yi(w)] and separately estimate
the two terms E[Yi(w′)] and E[Yi(w)]. To estimate the second term, E[Yi(w)] we construct
subclasses or strata based on p(w|x). Let qp(w|x)j be the quintiles of p(w | Xi) in the sample.
Then the average value of Yi(w) in subclass j is estimated as
µˆjw =
1
Njw
∑
i:q
p(w|x)
j−1 <p(w|Xi)≤qp(w|x)j ,Wi=w
Y obsi ,
where Njw is the number of units with q
p(w|x)
j−1 < p(w | Xi) ≤ qp(w|x)j and Wi = w. The overall
average of Yi(w) is then estimated as
Eˆ[Yi(w)] =
5∑
j=1
Nw
N
· µˆjw.
The key is that, in contrast to what is done in the binary treatment case, we do not
construct subclasses defined by similar values for the T − 1 propensity scores such that we
can estimate causal effects within the subclasses. Instead we construct subclasses defined
by similar values for a single propensity score at a particular treatment level so that we can
estimate the average potential outcome for that treatment level within the subclasses, and we
do so separately for each treatment level, with different subclasses for each treatment level.
14
In the binary treatment case this amounts to the same thing because the two propensity
scores p(1|x) and p(2|x) are linearly related, but in the multi-level case these two approaches
are different.
6 Assessing And Ensuring Overlap
6.1 Assessing balance
We focus on assessing balance in the covariate distributions in terms of the propensity score
as well as directly in terms of the covariates, following the discussion in Imbens & Rubin
(2015) for the binary case. For each treatment level w, we calculate the average values for
each component of the covariate vectors and their corresponding sample variances:
Xw = N
−1
w
∑
i:Wi=w
Xi, and S2X,w = (Nw − 1)−1
∑
i:Wi=w
(Xi −Xw)2.
Define also for each treatment level the average value of the covariates for units with a
treatment level different from w and the average variance:
Xw = (N −Nw)−1
∑
i:Wi 6=w
Xi, and S2X|W = T
−1
T∑
i=1
S2X,w.
respectively. The first approach to assessing the covariate balance is to inspect the normalized
differences for each covariate and each treatment level:
ndCOVw = (Xw −Xw)/SX|W (7)
We can also assess balance by looking at the generalized propensity score. For each treatment
level we can calculate the normalized difference for the generalized propensity score for that
treatment level:
ndGPSw =
(
p(w | X)w − p(w | X)w
)
/Sp(w|X)|W (8)
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where p(w | X)w = N−1w
∑
i:Wi=w
p(w | Xi) and p(w | X)w = (N − Nw)−1
∑
i:Wi 6=w
p(w | Xi).
Finally, one may wish to plot a histogram of p(w | Xi) for the Nw units for Wi = w and a
histogram of p(w | Xi) for the N −Nw units with Wi 6= w in the same figure.
6.2 Improving Overlap
In many applications there are regions of the covariate space with low values for the probab-
ility of receiving one of the treatments. This is likely in the setting with a binary treatment,
but even more likely to be an issue in settings with many treatment levels. Of note, lack
of overlap affects the credibility of all methods attempting to estimate all pairwise average
causal effects from the common population. In that case we may wish to modify the estim-
ands to average only over the part of the covariate space with all treatment probabilities away
from zero. The question is how to choose the set of covariates with overlap. For the binary
treatment case, Crump et al. (2009) proposed a method for improving overlap by trimming
the sample. Specifically they suggest dropping units from the analysis with low and high
values of the propensity score. The threshold for dropping units is based on minimizing the
variance of the estimated average treatment effect on the trimmed sample. By trimming
the sample, this method generally alters the estimand to the so-called feasible estimand, by
changing the reference population. Using the feasible estimand is widely recommended in
the literature, as long as we are careful to characterize the resulting quantity of interest.
Here we generalize the Crump et al. (2009) approach to the multi-level treatment case. We
focus on average treatment effects for subsets of the covariate space. Formally, define the
conditional average treatment effect:
τ(w,w′|C) = E[Yi(w′)− Yi(w) | Xi ∈ C].
The semiparametric efficiency bound for τ(w,w′ | C) is, building on the work by Hahn (1998)
and Hirano, Imbens, and Ridder (2003), under homoskedasticity and constant treatment
16
effects,
V(w,w′|C) = σ
2
pr(Xi ∈ C)E
[
1
p(w|Xi) +
1
p(w′|Xi) | Xi ∈ C
]
.
In the binary case Crump et al. (2009) proposed choosing C to minimize V(w,w′ | C), which
leads to dropping units with p(1 | Xi) ≤ α and units with p(1 | Xi) ≥ 1 − α, with α an
estimable function of the marginal distribution of the propensity score.
For the multi-level treatment case we suggest focusing on the subset of the covariate
space C that minimizes
V(C) =
∑
w,w′
V(w,w′ | C) = 2σ
2
pr(Xi ∈ C)E
[
T∑
w=1
1
p(w | Xi) | Xi ∈ C
]
.
Under homoskedasticity and a constant treatment effect this will lead to a set C of the form
C =
{
Xi ∈ X
∣∣∣∣∣
T∑
w=1
1
p(w | Xi) ≤ λ
}
,
where the threshold λ satisfies
λ ≤ 2
pr
( T∑
w=1
(p(w | Xi))−1 ≤ λ
)E
[
T∑
w=1
1
p(w | Xi)
∣∣∣∣∣
T∑
w=1
1
p(w | Xi) ≤ λ
]
.
To implement the trimming method in practice in the multi-level treatment case we replace
the expectation by an average and then find the largest λ that satisfies the inequality.
7 A Simulation Study
In this section we assess the performance of the two new estimators in cases of multi-level
treatments (matching on the generalized propensity score, GPSM, and subclassification on
the generalized propensity score, GPSS) in a Monte Carlo study relative to five previously
proposed estimators, first the simple difference in average outcomes (DIF) by treatment
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status, second pairwise propensity score matching (PPSM) that compares two treatment
levels at a time using the binary propensity score matching on the units exposed to one
of those two treatment levels, third the estimator based on matching on the set of T − 1
propensity score set (PSSM), fourth the estimator based on weighting, and fifth, matching
on all covariates (COV). In the binary treatment and missing data case previous simulations
have found that weighting estimators can have high variability, e.g., Kang & Schafer (2007)
and Guo & Fraser (2010), especially if the probabilities are close to zero. Frolich (2004a)
found that the weighting estimator was inferior to pairwise matching estimators in terms of
root mean squared error. This is even more likely to be a concern in settings with multiple
treatment levels than in the binary treatment case because, with the probabilities for the
T treatment levels adding up to one, with T large some probabilities are likely to be close
to zero. Because in the binary treatment case it has been found that matching on high-
dimensional covariates is not practical for commonly found sample sizes (e.g., the theoretical
results in Abadie & Imbens, 2006), it is likely that in settings with many treatment levels
matching on all scores is not effective either. These results motivate us to compare the
seven estimators in settings with a large number of treatment levels, and where some of the
treatment levels have low probability for some covariate values. In the simulations we focus
on two designs, one with three treatment levels and one with six treatment levels, and both
with six covariates.
In the first design with three treatment levels the covariates X1i, X2i, and X3i are mul-
tivariate normal with means zero, variances of (2, 1, 1) and covariances of (1,−1,−0.5); X4i ∼
U [−3, 3];X5i ∼ χ21; andX6i ∼ Bernoulli(0.5), withXTi = (1, X1i, X2i, X3i, X4i, X5i, X6i). The
three treatment groups are formed using multinomial regression model
(Di(1), Di(2), Di(3)) ∼ Multinom(p(1|Xi), p(2|Xi), p(3|Xi)),
where Di(w) is the treatment indicator, i.e. Di(w) = 1, if the unit i belongs to treat-
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ment w, and p(w|Xi) = exp(XTi βw)/
∑3
w′=1 exp(X
T
i βw′), βT1 = (0, 0, 0, 0, 0, 0, 0), βT2 = 0.7×
(0, 1, 1, 1,−1, 1, 1), and βT3 = 0.4×(0, 1, 1, 1, 1, 1, 1). The outcome design is Yi(w) = XTi γw+ηi
with ηi ∼ N(0, 1), γT1 = (−1.5, 1, 1, 1, 1, 1, 1), γT2 = (−3, 2, 3, 1, 2, 2, 2), and γT3 = (1.5, 3, 1, 2,
−1,−1,−1). The sample sizes are Nw = 500, for w = 1, 2, 3.
We compare the seven estimators over 1000 datasets. The generalized propensity scores
are estimated using multinomial logistic regression model with all covariates entering the
model linearly. 95% confidence intervals for point estimates were calculated using: (a) 2.5
and 97.5 percentiles from 1000 bootstrap samples for DIF, GPSS, and weighting; (b) point
estimate ±1.96 × (variance)1/2 for Abadie & Imbens (2006) variance estimator for COV
and PSSM; and for Abadie & Imbens (2012) variance estimator for PPSM and GPSM,
which takes into account the uncertainty of the matching procedure and the uncertainty of
estimating generalized propensity scores, as in Web Appendix.
Table 1 presents the bias, root mean squared error (RMSE) and coverage of 95% confid-
ence intervals. DIF shows that there are substantial biases associated with the covariates.
PPSM compares two treatment levels at a time using the units exposed to one of those
two treatment levels, which focuses on different populations of inference each time. This
leads to inconsistency for simultaneous comparison of treatment levels. One implication is
that τˆ(1, 2) + τˆ(2, 3) + τˆ(3, 1) 6= 0. Even with only three treatment levels, and so only two
propensity scores to match on, PSSM did not control the bias well. The four remaining pro-
cedures, including COV, GPSM and GPSS, and weighting, do a fairly good job of reducing
the bias for all average treatment effects. Among these four, COV has smallest RMSE. For
inference, asymptotic 95% confidence intervals provide coverage very close to the nominal
coverage for GPSM, which confirms our inference theory in Web Appendix. Asymptotic 95%
confidence intervals for GPSS and weighting are also fairly accurate, but COV leads to un-
dercoverage, consistent with the results in Abadie & Imbens (2006) on the bias of matching
estimators with multiple covariates.
In the second design with six treatment levels, we consider propensity score design as
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p(w | Xi) = exp(XTi βw)/
∑6
w′=1 exp(X
T
i βw′), where βT1 = (0, 0, 0, 0, 0, 0, 0), βT2 = 0.4 ×
(0, 1, 1, 2, 1, 1, 1), βT3 = 0.6 × (0, 1, 1, 1, 1, 1,−5), βT4 = 0.8 × (0, 1, 1, 1, 1, 1, 5), βT5 = 1.0 ×
(0, 1, 1, 1,−2, 1, 1), and βT6 = 1.2 × (0, 1, 1, 1,−2,−1, 1). The outcome design is Yi(w) =
XTi γw, with γT1 = (−1.5, 1, 1, 1, 1, 1, 1), γT2 = (−3, 2, 3, 1, 2, 2, 2), γT3 = (3, 3, 1, 2,−1,−1,−4),
γT4 = (2.5, 4, 1, 2,−1,−1,−3), γT5 = (2, 5, 1, 2,−1,−1,−2), and γT6 = (1.5, 6, 1, 2,−1,−1,−1)
with ηi ∼ N(0, 1). The sample sizes are Nw = 1000, for all w.
In Figure 1 we present the results for the estimators for the fifteen average treatment
effects. The simulation setup creates six treatment groups with strong separation in covariate
distributions, which makes it fundamentally difficulty removing all biases in estimating fifteen
treatment effects simultaneously. Overall GPSM outperforms the other methods in terms of
bias and coverage rates, with the coverage rate for nominal 95% confidence intervals never
going below 0.75. To assess the performance of the weighting estimator it is useful to look at
the weights that underly the estimator. Normalizing the weights so that they average to Nw
for each of the treatment levels, the maximum weight for units in each of the treatment levels
is 16.9 (treatment level one), 21.2 (treatment level two), 50.0 (treatment level three), 64.9
(treatment level four), 21.2 (treatment level five), and 185.1 (treatment level six). Even in
the three treatment level case these maximum weights are substantial. There the maximum
weight for units in each of the treatment levels is 16.5 (treatment level one), 95.8 (treatment
level two), and 17.9 (treatment level three).
In an extended simulation (see Web Appendix), we compare the performance of the
estimators under the combinations of (w/o) trimming and (correct/incorrect) generalized
propensity score model. When the propensity score model is incorrect, the performance for
all methods based on the propensity score deteriorates. In particular, the weighting estimator
shows huge bias and variance and poor coverage for all parameters. GPSM is inferior to COV
in terms of bias and variance; however, it presents better coverage for ten parameters out of
fifteen parameters. This suggests that when covariates are high dimensional, the inference
for COV is not satisfactory. After trimming, bias and variance are greatly reduced and
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Table 1: Simulation Results, Design I. Estimators: (1) DIF, simple difference in outcomes for
units with different treatment levels; (2)PPSM: pairwise comparison using binary propensity
score matching; (3) PSSM: matching on the propensity score set; (4) W: weighting estimator;
(5) COV: matching on all covariates; (6) GPSM: matching on the generalized propensity
score; (7) GPSS: stratification on the generalized propensity score. Variance estimators: (1)
bootstrapping variance estimator for DIF, GPSS, and W; (2) Abadie and Imbens (2006)
variance estimator for COV matching and PSSM; (3) Abadie and Imbens (2012) variance
estimator for PPSM and GPSM.
Bias RMSE Coverage 95% CI
τ(1, 2) τ(1, 3) τ(2, 3) τ(1, 2) τ(1, 3) τ(2, 3) τ(1, 2) τ(1, 3) τ(2, 3)
DIF 1.34 0.57 -0.77 1.38 0.60 0.83 0.01 0.26 0.41
PPSM −0.6 −1.1 −0.8 0.77 1.16 0.91 0.80 0.001 0.74
PSSM 0.21 0.19 -0.02 0.27 0.33 0.29 0.90 0.92 0.98
W 0.05 0.02 -0.03 0.55 0.43 0.53 0.91 0.97 0.94
COV 0.29 0.19 -0.11 0.33 0.22 0.20 0.75 0.88 0.99
GPSM 0.14 0.04 -0.10 0.56 0.36 0.61 0.95 0.95 0.95
GPSS 0.31 0.05 -0.27 0.53 0.24 0.54 0.91 0.99 0.94
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Figure 1: Simulation Results, Design II.
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coverage is improved for all parameters for GPSM, GPSS and weighting, which suggests
that trimming can improve the performance of GPS based methods.
8 An Application
We re-examined data from the REFLECTIONS (Real-world Examination of Fibromyalgia:
Longitudinal Evaluation of Costs and Treatments) study. REFLECTIONS was a 12-month
prospective observational study of patients being treated for fibromyalgia at 58 outpatient
sites in the US and Puerto Rico. Patients had to be at least 18 years of age and initiating
a new pharmacologic treatment for fibromyalgia. In keeping with the observation nature
of the study, inclusion and exclusion criteria were kept to a minimum, no requirements on
the nature of the fibromyalgia treatment were made, and physicians decisions regarding the
proper treatment and care of patients were made in the course of normal clinical practice.
Data from patients were collected at baseline during a standard office visit and at 1, 3, 6,
and 12 months post baseline via a computer assisted telephone interviews. For details on
the design of REFLECTIONS see Robinson et al. (2012).
For this example, we focused on the analysis of three fibromyalgia medication cohorts
(Peng et al., 2015): patients treated with an opioid (either monotherapy or with other
medications), patients treated with tramadol but not an opioid, and patients not treated
with tramadol or an opioid (referred to as the Other cohort). The outcome variable utilized
here is the total score of Fibromyalgia Impact Questionnaire (FIQ), which is composed of
items measuring physical functioning, number of days the patient felt well, number of days
the patient felt unable to work due to FM symptoms, and patient ratings of work difficulty,
pain intensity, fatigue, morning tiredness, stiffness, anxiety, and depression. The total score
ranges from 0 to 80 with lower scores indicating better outcomes, and research suggests a
14% reduction (or 7.6 points in this sample) is clinically relevant (Bennett et al., 2009). The
objective is to produce causal inference pairwise comparisons between the cohorts all based
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on the same population (the population represented by the trimmed sample), in order to test
the study hypothesis that there is no difference in FIQ total score among the three cohorts.
The generalized propensity scores (3 estimated probabilities for each patient) were com-
puted using a multinomial model with 32 predictors from demographics, baseline clinical
characteristics, comorbidities, resource use, prior fibromyalgia treatment, and physician in-
formation.
To help address lack of overlap of the populations, the modified Crump (Crump et al.,
2009) algorithm of Section 7 was applied. With the REFLECTIONS data, λ = 29.88, and
thus patients were trimmed if their
∑T
w=1 1/p(w|Xi) value was greater than 43.52. This
resulted in removal of 363 patients (25% of the sample), with 31(9%) from the Opioid cohort
(OPI), 17(8%) of the Tramadol cohort (TRA), and 315(34%) from the Other cohort (OTH).
Thus, the analysis cohort included 1101 patients (308 OPI, 188 TRA, 605 OTH).
The trimming primarily removed patients in OTH who had high propensities for being in
OTH (and low propensities for either OPI or TRA) and were under-represented in OPT and
TRA. Using the trimmed sample, generalized propensity score matching was implemented
following the steps in Section 5 to produce counterfactual outcomes (imputed FIQ total
scores) for each patient and cohort. The quality of the matches appeared acceptable, with
the mean difference in propensity scores for the matched patients ranging from 0.0012 to
0.0014 across the cohorts and the largest matched pair with a difference of 0.035.
The unadjusted mean changes(sd) from baseline to endpoint (12 months post baseline)
for the FIQ total score in the trimmed cohort were −2.4(12.3) for OPI, −3.7(14.0) for
TRA, and −4.2(13.4) for OTH, indicating small numerical improvement in pain symptoms.
Table 2 summarizes the comparative analysis of the FIQ total score improvement among
the 3 cohorts on the trimmed sample using generalized propensity score matching (GPSM)
and stratification (GPSS). As a comparison, results using no bias adjustment (Difference
in Means), propensity score set matching (PSSM), weighting (W), and covariate matching
(COV) are included. Without bias adjustment, no cohort differences reach the level of
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Table 2: Analysis results: Change from Baseline to Endpoint (12 Months) for the FIQ total
score. OPI = Opioid Cohort; TRA = Tramadol Cohort; OTH = Other Cohort. TRA-OPI
indicates the estimated difference in change from baseline scores for the Tramadol Cohort
minus the same value for the Opioid cohort. Thus, negative values indicate greater reduction
in symptoms for the first cohort. Analyses are on the Trimmed sample. Confidence Intervals
were calculated using the same methods as for simulated study above.
Pairwise Differences Means (95% CI)
Method TRA - OPI OTH- OPI OTH - TRA
DIF -1.1 (-3.8, 1.1) -1.7(-3.5, 0.3) -0.6 (-2.6, 2.2)
PPSM -3.9 (-7.2, -0.6) -1.4 (-3.4, 0.6) -1.8 (-4.2, 0.6)
PSSM -2.5 (-6.6, 1.6) -1.9 (-4.1, 0.4) 0.7 (-3.1, 4.4)
W -0.8 (-5.4, 4.7) -0.3 (-3.8, 5.1) 0.4 (-2.3, 4.0)
COV -1.6 (-4.8, 1.5) -1.5 (-3.8, 0.9) 0.2 (-2.5, 2.8)
GPSM -1.6 (-4.3,1.1) -0.9 (-2.8,1.1) 0.7 (-1.8,3.2)
GPSS -1.6 (-5.5, 1.2) -1.2 (-4.1, 0.9) 0.4 (-2.2, 3.8)
statistical significance, though OTH demonstrated marginally greater reductions than OPI
(p = 0.058). Similarly, none of the adjusted differences led to any statistical significant
findings, indicating similar health condition improvements at 12 months over baseline among
the three cohorts. Note that by using the same population across all comparisons, pairwise
differences across the cohorts using the generalized propensity scoring methods (GPSM,
GPSS) are consistent, whereas using PPSM this is not true (the PPSM estimates suggest
that changing the treatment from OPI to TRA leads to an average effect of -3.9, changing
the treatment effect from TRA to OTH leads to an average effect of -1.8, and changing the
treatment from OPI to OTH leads to an average effect of -1.4, which cannot all be true at
the same time). This illustrates the impact of differing populations can have when using
PPSM.
9 Conclusion
In this paper, we develop new methods for estimating causal treatment effects using obser-
vational data in settings with multiple (more than two) treatment levels. Existing methods
require additional assumptions assuming the existence of a scalar balance score, so as to
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facilitate matching and subclassification. We show that, contrary to claims in the literature,
matching and subclassification methods using the propensity score generalize naturally to
the multi-level treatment case. We focus on matching and subclassification on the general-
ized propensity score using the notion of weak unconfoundedness, and show that adjusting
for a scalar function of the covariates can remove all biases associated with differences in
observed covariates.
As with other propensity based analyses, this approach depends on correct specification
of propensity score modeling, and does not resolve the potential for bias due to unmeasured
confounding. An initial simulation study and example demonstrated the potential benefits
of the proposed approach at reducing bias and providing causal inference comparisons for
multiple cohorts on a common population.
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